Under 10% of people that would benefit from obesity jabs such as Wegovy can access them, warns the WHO as it issues its first advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for broader and more equitable availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our latest guidelines affirms that obesity is a chronic disease that can be treated with holistic and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key obstacles to broad access to the injections that can help people shift considerable weight, explains the organization.
Skinny Jab Shortage
Even in the present most optimistic scenario, the production of these medications might only reach around 100 million people – under 10% of eligible patients, according to the WHO.
The guideline urges governments and firms to increase availability, through approaches such as voluntary licensing.
Exclusive production rights on semaglutide – the primary component of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Injections Operate
The injections replicate a natural hormone to reduce digestion speed, reduce hunger and increase satiety so individuals eat less.
Individuals usually start to lose weight within a few weeks of commencing the regular doses.
Evidence points to people may regain a significant portion after a year of stopping the medication, when their normal food cravings come back.
Being overweight or obese increases your risk for experiencing medical conditions, including type 2 diabetes, heart disease, stroke, and certain cancers.
Excess weight concerns people in all nations and was associated with millions of fatalities worldwide in 2024, per the health agency.
